Immunotherapy

Michael B. Atkins MD and Antoni Ribas MD PhD review data from key presentations on immunotherapy from the 2015 clinical oncology meeting in Chicago.

Share

Program Content

Activities

  • CheckMate 057
    CheckMate 057: Nivolumab Superior to Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2015

    Expires: May 29, 2016

  • CA209-040 Nivolumab in HCC
    CA209-040: Nivolumab With Promising Safety and Antitumor Activity in Advanced HCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2015

    Expires: May 29, 2016

  • MMR Deficiency
    Tumors Deficient in Mismatch Repair Particularly Susceptible to Immune Checkpoint Blockade
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2015

    Expires: May 29, 2016

  • CheckMate 017
    CheckMate 017: Nivolumab Superior to Docetaxel in Previously Treated Advanced Squamous NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2015

    Expires: May 30, 2016

  • Pembrolizumab in SCLC
    KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1-Positive Extensive-Stage SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2015

    Expires: May 30, 2016

  • CheckMate 067
    CheckMate 067: Nivolumab + Ipilimumab and Nivolumab Alone Superior to Ipilimumab Alone in Previously Untreated Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2015

    Expires: May 31, 2016

  • Immunogenic Antigens
    Molecular Insight Into Lack of Response of Some Melanomas to Immunotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2015

    Expires: June 01, 2016

  • PD-L1/MEK/BRAF in Melanoma
    Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2015

    Expires: June 01, 2016

  • Biomarkers for Nivolumab in mRCC
    Predictive Biomarkers and Nivolumab Activity in mRCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2015

    Expires: June 02, 2016

  • KEYNOTE-012: Pembrolizumab
    KEYNOTE-012: Pembrolizumab Shows Promising Antitumor Activity and Safety in Advanced Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Atezolizumab in UBC
    Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2015

    Expires: June 03, 2016

  • Downloadable Slideset
    Cancer Immunotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 25, 2015

    Expires: August 23, 2016

  • Nivolumab ± Ipilimumab in SCLC
    CheckMate 032: Nivolumab ± Ipilimumab With Promising Activity in Recurrent SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation